{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:54:40Z","timestamp":1771955680282,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004172","name":"Mersin \u00dcniversitesi","doi-asserted-by":"publisher","award":["2021-2-TP3-4493"],"award-info":[{"award-number":["2021-2-TP3-4493"]}],"id":[{"id":"10.13039\/501100004172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05186-9","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T07:02:15Z","timestamp":1723100535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of homeobox protein B13 (HOXB13) gene G84E mutation in patients with prostate cancer"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4798-7389","authenticated-orcid":false,"given":"Melih","family":"B\u0131y\u0131ko\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7004-790X","authenticated-orcid":false,"given":"Rojda","family":"Tanr\u0131verdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8624-0149","authenticated-orcid":false,"given":"Murat","family":"Bozlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-4192","authenticated-orcid":false,"given":"Samet","family":"\u015eenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-604X","authenticated-orcid":false,"given":"\u015eenay Balc\u0131","family":"Fidanc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-0260","authenticated-orcid":false,"given":"L\u00fcl\u00fcfer","family":"Tamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-414X","authenticated-orcid":false,"given":"Erdem","family":"Akbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"5186_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin Jan. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin Jan"},{"key":"5186_CR2","doi-asserted-by":"publisher","unstructured":"Fleshner K, Carlsson SV, Roobol MJ (2017) The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA, Nature Reviews Urology, vol. 14, no. 1. Nature Publishing Group, pp. 26\u201337, Jan. 01, https:\/\/doi.org\/10.1038\/nrurol.2016.251","DOI":"10.1038\/nrurol.2016.251"},{"key":"5186_CR3","doi-asserted-by":"publisher","unstructured":"Sung H, Global Cancer Statistics (2020) : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin, vol. 71, no. 3, pp. 209\u2013249, May 2021, https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"5186_CR4","doi-asserted-by":"crossref","unstructured":"Hemminki K (Apr. 2012) Familial risk and familial survival in prostate cancer. World J Urol 30:143\u2013148. no. 210.1007\/s00345-011-0801-1","DOI":"10.1007\/s00345-011-0801-1"},{"key":"5186_CR5","doi-asserted-by":"publisher","unstructured":"Randazzo M et al (Apr. 2016) A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European randomised study of screening for prostate Cancer (ERSPC, Aarau). BJU Int 117(4):576\u2013583. https:\/\/doi.org\/10.1111\/bju.13310","DOI":"10.1111\/bju.13310"},{"key":"5186_CR6","doi-asserted-by":"publisher","unstructured":"Seibert TM Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention, European Urology, vol. 83, no. 3., Elsevier BV et al (2023) pp. 241\u2013248, Mar. 01, https:\/\/doi.org\/10.1016\/j.eururo.2022.12.021","DOI":"10.1016\/j.eururo.2022.12.021"},{"key":"5186_CR7","doi-asserted-by":"publisher","unstructured":"Heidegger I et al (2019) Hereditary prostate cancer \u2013 Primetime for genetic testing? Cancer Treatment Reviews, vol. 81. W.B. Saunders Ltd, Dec. 01, https:\/\/doi.org\/10.1016\/j.ctrv.2019.101927","DOI":"10.1016\/j.ctrv.2019.101927"},{"key":"5186_CR8","doi-asserted-by":"publisher","unstructured":"Pritchard CC et al (2016) Aug., Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer, New England Journal of Medicine, vol. 375, no. 5, pp. 443\u2013453, https:\/\/doi.org\/10.1056\/nejmoa1603144","DOI":"10.1056\/nejmoa1603144"},{"key":"5186_CR9","unstructured":"Schaeffer EM et al National Comprehensive Cancer Network (NCCN) Prostate Cancer Guideline Version 1.2023, 2023. [Online]. Available: https:\/\/www.nccn.org\/home\/"},{"key":"5186_CR10","doi-asserted-by":"publisher","unstructured":"Halabi S et al (2024) The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3017\/3405221\/ccr-23-3017.pdf","DOI":"10.1158\/1078-0432.CCR-23-3017\/3405221\/ccr-23-3017.pdf"},{"issue":"2","key":"5186_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5114\/pjp.2019.87103","volume":"70","author":"M Heise","year":"2019","unstructured":"Heise M, Jarzemski P, B\u0105k A, Junkiert-Czarnecka A, Pilarska-Deltow M, Haus O (2019) G84e germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men. Pol J Pathol 70(2):127\u2013133. https:\/\/doi.org\/10.5114\/pjp.2019.87103","journal-title":"Pol J Pathol"},{"key":"5186_CR12","doi-asserted-by":"publisher","unstructured":"Kurihara S et al (2022) Aug., Variants in HOXB13, G132E and F127C, Are Associated With Prostate Cancer Risk in Japanese Men, Cancer Diagnosis & Prognosis, vol. 2, no. 5, pp. 542\u2013548, https:\/\/doi.org\/10.21873\/cdp.10139","DOI":"10.21873\/cdp.10139"},{"key":"5186_CR13","doi-asserted-by":"publisher","unstructured":"Na R et al (2022) Mar., The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients, Br J Cancer, vol. 126, no. 5, pp. 791\u2013796, https:\/\/doi.org\/10.1038\/s41416-021-01622-4","DOI":"10.1038\/s41416-021-01622-4"},{"key":"5186_CR14","doi-asserted-by":"publisher","unstructured":"Dupont WD, Breyer JP, Johnson SH, Plummer WD, Smith JR (Dec. 2021) Prostate cancer risk variants of the HOXB genetic locus. Sci Rep 11(1). https:\/\/doi.org\/10.1038\/s41598-021-89399-7","DOI":"10.1038\/s41598-021-89399-7"},{"key":"5186_CR15","doi-asserted-by":"crossref","unstructured":"Boyle JL et al (2020) Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer,., [Online]. Available: https:\/\/doi.org\/10","DOI":"10.1200\/PO.19.00284"},{"key":"5186_CR16","doi-asserted-by":"publisher","unstructured":"Hamid SM et al (Mar. 2014) HOXB13 contributes to G1\/S and G2\/M checkpoint controls in prostate. Mol Cell Endocrinol 383:1\u20132. https:\/\/doi.org\/10.1016\/j.mce.2013.12.003","DOI":"10.1016\/j.mce.2013.12.003"},{"key":"5186_CR17","doi-asserted-by":"publisher","unstructured":"Kavalci E, Onder AU, Brusgaard K, Bostanci A, Selhanoglu MY, Serakinci N (Feb. 2021) Identification of genetic biomarkers in urine for early detection of prostate cancer. Curr Probl Cancer 45(1). https:\/\/doi.org\/10.1016\/j.currproblcancer.2020.100616","DOI":"10.1016\/j.currproblcancer.2020.100616"},{"key":"5186_CR18","doi-asserted-by":"publisher","unstructured":"Trendowski MR et al (2022) Germline variants in DNA damage repair genes and HOXB13 among black patients with early-onset prostate Cancer. https:\/\/doi.org\/10.1200\/PO.22","DOI":"10.1200\/PO.22"},{"key":"5186_CR19","doi-asserted-by":"publisher","unstructured":"Darst BF et al (May 2022) A rare germline HOXB13 variant contributes to risk of prostate Cancer in men of African ancestry. Eur Urol 81(5):458\u2013462. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.023","DOI":"10.1016\/j.eururo.2021.12.023"},{"key":"5186_CR20","doi-asserted-by":"publisher","unstructured":"Song SH et al (2023) Germline DNA-Repair genes and HOXB13 mutations in Korean men with metastatic prostate Cancer: data from a large Korean cohort. World J Men\u2019s Health 41. https:\/\/doi.org\/10.5534\/wjmh.220190","DOI":"10.5534\/wjmh.220190"},{"key":"5186_CR21","doi-asserted-by":"publisher","unstructured":"Lin X et al (2013) Jan., A novel Germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men, Prostate, vol. 73, no. 2, pp. 169\u2013175, https:\/\/doi.org\/10.1002\/pros.22552","DOI":"10.1002\/pros.22552"},{"key":"5186_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.021","author":"O Bergengren","year":"2023","unstructured":"Bergengren O et al (2023) 2022 update on prostate Cancer epidemiology and risk Factors\u2014A systematic review. Eur Urol Elsevier B V. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","journal-title":"Eur Urol Elsevier B V"},{"key":"5186_CR23","doi-asserted-by":"publisher","unstructured":"Shao WH, Zheng CF, Ge YC, Chen XR, Zhang BW, Wang GL, Zhang WD Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older. Asian J Androl 2023 Jan-Feb ;25(1):132\u2013136. https:\/\/doi.org\/10.4103\/aja202223. PMID: 35532557; PMCID: PMC9933963.","DOI":"10.4103\/aja202223"},{"key":"5186_CR24","doi-asserted-by":"publisher","DOI":"10.36255\/exon","author":"BS Raghallaigh","year":"2022","unstructured":"Raghallaigh BS (2022) The role of Family History and Germline Genetics in prostate Cancer Disease Profile and Screening. Exon Publications, 2022.   https:\/\/doi.org\/10.36255\/exon-publications-urologic-cancers","journal-title":"Exon Publications"},{"key":"5186_CR25","unstructured":"Isaacs WB, Cooney KA, Xu J (2019) Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13"},{"key":"5186_CR26","unstructured":"Kote-Jarai Z et al (2015) Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characterisitics and clinical outcomes,., [Online]. Available: http:\/\/annonc.oxfordjournals.org\/"},{"key":"5186_CR27","doi-asserted-by":"crossref","unstructured":"Ewing CM et al (2012) Germline Mutations in HOXB13 and Prostate Cancer Risk,., [Online]. Available: http:\/\/cran.r-project.org","DOI":"10.1016\/j.yuro.2012.06.012"},{"key":"5186_CR28","doi-asserted-by":"publisher","unstructured":"Akbari MR et al (2012) Aug., Association between germline HOXB13 G84E mutation and risk of prostate cancer, J Natl Cancer Inst, vol. 104, no. 16, pp. 1260\u20131262, https:\/\/doi.org\/10.1093\/jnci\/djs288","DOI":"10.1093\/jnci\/djs288"},{"key":"5186_CR29","doi-asserted-by":"publisher","unstructured":"Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR (2012) Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer, Cancer Epidemiology Biomarkers and Prevention, vol. 21, no. 8, pp. 1348\u20131353, Aug. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-0495","DOI":"10.1158\/1055-9965.EPI-12-0495"},{"key":"5186_CR30","doi-asserted-by":"publisher","unstructured":"Klu\u017aniak W et al (2013) Apr., The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland, Prostate, vol. 73, no. 5, pp. 542\u2013548, https:\/\/doi.org\/10.1002\/pros.22594","DOI":"10.1002\/pros.22594"},{"key":"5186_CR31","doi-asserted-by":"publisher","unstructured":"Storebjerg TM et al (Oct. 2016) Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. BJU Int 118(4):646\u2013653. https:\/\/doi.org\/10.1111\/bju.13416","DOI":"10.1111\/bju.13416"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05186-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:20:19Z","timestamp":1735852819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05186-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5186"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05186-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Mersin University Local Ethics Committee on 23.06.2021, under committee decision number 2021\/472.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publishing personal information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflict of interest was declared by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"476"}}